US Patent

US12121582 — Injectable pharmaceutical formulations of lefamulin

Formulation · Assigned to Nabriva Therapeutics AG · Expires 2036-06-14 · 10y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects injectable pharmaceutical formulations of lefamulin, specifically buffered to a pH-value of 2 to 6.

USPTO Abstract

The present invention relates to an injectable pharmaceutical formulation comprising a compound of formula (I) the formulation being buffered to a pharmaceutically acceptable pH-value, especially a pH-value of from 2 to 6, in particular a pH value of from 3 to 5.5, preferred a pH-value of about 4 to 5, particularly preferred about 5.

Drugs covered by this patent

Patent Metadata

Patent number
US12121582
Jurisdiction
US
Classification
Formulation
Expires
2036-06-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Nabriva Therapeutics AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.